Continue to Site

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Cardiovascular

This is a picture of anatomical heart to go along with MassDevice's cardiovascular device news home, courtesy of Kenny Eliason on Unsplash.Welcome to MassDevice's Cardiovascular Hub, your resource for the latest news in cardiac implants, structural heart, heart valves, stents and more. Stay informed about the innovations and business news shaping the cardiovascular device industry.

🫀 Narrow your focus with these categories:
Cardiac Implants | Structural Heart | Pulsed-Field Ablation

Here are top cardiology features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):

+ The latest AI-powered cardiology devices you need to know
+ LVADs save lives: So why aren’t more available?
+ How Medtronic uses nitinol to improve the structure and effectiveness of heart devices
+ How Abbott designed the world’s first dual-chamber leadless pacemaker system
+ J&J used RWE for expanded indications — and you can, too
+ 7 cardiology startups you need to know

Latest Cardiology News

LeMaitre ends 2009 in the black

By Leave a Comment

LeMaitre Vascular Inc. (NSDQ:LMAT) ended 2009 swinging from red to black, riding strong sales in its vascular division to positive top- and bottom-line growth for the year.

The Burlington, Mass.-based peripheral vascular device maker posted sales of $13.6 million during the three months ended Dec. 31, 2009, up 13 percent compared with the $12 million in sales the company reported during the same period in 2008.

The increased sales helped the company boost its bottom line to $1.3 million, compared to a $312,000 profit for Q4 2008.

ATS Medical trims net loss by 68 percent in 2009

By Leave a Comment

ATS Medical Inc. (NSDQ:ATSI) reported sales of $18.7 million during the fourth quarter, an increase of 4 percent when compared to the $18 million the company reported during the same period in 2008.

The Minneapolis, Minn.-based heart valve repair products company managed to trim its net loss to $3.4 million for the three months ended Dec. 31, 2009, a 62 percent decrease from the $8.5 million the company lost during the same period last year.

For the year, ATS managed to narrow its net losses by 68 percent, reporting a loss of just over $6 million on $75 million in sales, compared to a $19 million loss on $66 million in sales during 2008.

Rudman and Pepper announce retirements from Boston Scientific board

By Leave a Comment

Boston Scientific Corp. (NYSE:BSX) said two of its current board members have decided not to seek re-election for their seats at the company’s next annual meeting and will be retiring from their service to the company.

Former Sen. Warren Rudman, a board member at Boston Scientific for the past 11 years, and John Pepper, who has served on and off since 1999, will both retire following the expiration of their terms, the company announced.

Rudman, who came on board at the Natick, Mass.-based medical device giant in 1999, served two terms as senator for New Hampshire from 1980-1992. He is 79 years old and sits on the board of several funds managed by the Dreyfus Corp.

Johnson & Johnson appeals patent ruling

By Leave a Comment

Johnson & Johnson (NYSE:JNJ) appealed a federal judge’s ruling that four of its Cordis Corp. subsidiary’s drug-eluting stent patents are invalid, the latest salvo in its long-running infringement battle with Boston Scientific Corp. (NYSE:BSX).

The patents in question are at the heart of complicated legal wrangling involving the Natick, Mass.-based medical device giant, its New Brunswick, N.J.-based rival and its competitor/partner Abbott (NYSE:ABT). The dispute centers around Boston Scientific’s Promus stent, a private-label version of Abbott’s Xience V stent, and the Cordis Cypher.

Medtronic wins a round in valve patent fight against Edwards

By Leave a Comment

Medtronic Inc. (NYSE:MDT) won a round in its patent fight against Edwards Lifesciences Inc. (NYSE:EW), as the medical device giants prepare for a showdown in the U.S. District Court for Delaware in late March over a patent involving an aortic valve replacement.

The Appellate Court of Düsseldorf, Germany, upheld a German lower court’s ruling that Medtronic’s CoreValve transcatheter aortic valve does not infringe on Edwards Lifesciences’s German patent.

The CoreValve system is designed to enable the replacement of a diseased aortic valve without open heart surgery. Edwards claimed the technology infringed on a patent it held in Germany and has filed similar suits in the U.K. and the U.S.

Md. hospital, doc slapped with class action suit in alleged unneeded stents case

By Leave a Comment

A doctor at St. Joseph Medical Center in Towson, Md., and the hospital are defendants in a class action lawsuit accusing them of implanting unnecessary coronary stents in 369 patients.

The hospital’s cardiology business is already under federal investigation over the procedures, which came to light after St. Joseph’s sent letters to the patients informing them that their stent implantations might not have been needed.

Boston Scientific settles Johnson & Johnson stent patent spat for $1.7 billion

By Leave a Comment

Boston Scientific Corp. (NYSE:BSX) will pay Johnson & Johnson (NYSE:JNJ) $1.725 billion to settle a quartet of patent infringement lawsuits concerning the companies’ lines of cardiovascular stents.

The Natick, Mass.-based medical devices monolith agreed to the settlement, which calls for it to pay J&J $1 billion today and the rest in about a year, said it plans to post a $745 million letter of credit to cover the $725 million balance and interest. The deal won’t have "an appreciable impact" on Boston Scientific’s debt covenants, according to a press release, and will leave BSX with "significant liquidity" under its credit facilities.

Abbott’s Q4, 2009 vascular sales rise

By Leave a Comment

Abbott (NYSE:ABT) reported strong sales for its vascular medical devices business, which posted double-digit growth during 2009 and rose 9.1 percent to $723 million during the fourth quarter, including the effects of foreign exchange rates.

The Chicago-area medical device monolith’s overall sales rose 10.6 percent to $8.79 billion during the three months ended Dec. 31. For the full year, total sales reached $30.77 billion, a 4.2 percent increase when exchange rates were taken into account.

Copyright © 2024 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy